Literature DB >> 8557325

Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera.

G A Losonsky1, J Yunyongying, V Lim, M Reymann, Y L Lim, S S Wasserman, M M Levine.   

Abstract

Although serum vibriocidal activity is used extensively as a marker of immunity to O1 Vibrio cholerae, there are limitations in this assay to detect instances of reexposure. We define the conditions operative in producing secondary vibriocidal responses in North American volunteers primed with either wild-type V. cholerae 1, 4, or 6 months later. Secondary serum vibriocidal responses occurred under two distinct secondary challenge conditions. The first occurred when secondary challenge produced a breakthrough in clinical protection. Following secondary exposure, 14 of 22 (64%) and 1 of 29 (3%) subjects with and without vibrio stool excretion, respectively, had secondary responses (P < 0.001); 5 of 6 (83%) and 10 of 45 (22%) subjects with or without diarrhea, respectively, mounted a secondary response (P = 0.006). The second condition occurred in the presence of full clinical protection but was dependent on the time interval between exposure. No subject (0 to 17) vaccinated with CVD 103-HgR and given homologous wild-type challenge within 4 months mounted a secondary vibriocidal response (P = 0.0009). The majority of the serum vibriocidal activity was of the immunoglobulin M (IgM) isotype, seen in 96 and 73% of subjects following primary and secondary exposure, respectively. Vibriocidal activity in the IgG fraction following primary and secondary exposures occurred with < or = 50% of volunteers; lipopolysaccharide (LPS)-specific IgG1 and IgG3 subclass responses supported the vibriocidal isotype data. However, following primary exposure, IgG4 LPS responses predominated, occurring in 81% of responding volunteers. These data suggest that, under certain conditions of secondary exposure to V. cholerae O1 antigens, when there is sufficient active local immunity present, there is a block of vibrio antigen resampling at the M cell level. We discuss the implications of and possible explanations for these findings.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557325      PMCID: PMC173720          DOI: 10.1128/iai.64.1.10-15.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera.

Authors:  W H Mosley; A S Benenson; R Barui
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

2.  Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and non-endemic cholera areas.

Authors:  A Ahmed; A K Bhattacharjee; W H Mosley
Journal:  J Immunol       Date:  1970-08       Impact factor: 5.422

3.  Induction of Vibrio cholerae specific biliary antibodies after oral immunisation with a cholera cell-wall fraction.

Authors:  H Champsaur; S Iscaki; O Bernard; A Dodin
Journal:  Lancet       Date:  1985-06-01       Impact factor: 79.321

4.  The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement.

Authors:  S H Neoh; D Rowley
Journal:  J Infect Dis       Date:  1970-05       Impact factor: 5.226

5.  Duration of infection-derived immunity to cholera.

Authors:  M M Levine; R E Black; M L Clements; L Cisneros; D R Nalin; C R Young
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

6.  Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae.

Authors:  M L Clements; M M Levine; C R Young; R E Black; Y L Lim; R M Robins-Browne; J P Craig
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

Review 7.  Mechanisms of disease and immunity in cholera: a review.

Authors:  J Holmgren; A M Svennerholm
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

8.  Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine.

Authors:  N F Pierce; J B Kaper; J J Mekalanos; W C Cray; K Richardson
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

9.  The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients.

Authors:  W H Mosley; S Ahmad; A S Benenson; A Ahmed
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

10.  THE ISOLATION AND BIOLOGICAL ACTIVITIES OF RABBIT GAMMA M- AND GAMMA G-ANTI-SALMONELLA TYPHIMURIUM ANTIBODIES.

Authors:  J B ROBBINS; K KENNY; E SUTER
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more
  30 in total

1.  Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection.

Authors:  Douglas J Haney; Michael D Lock; Marc Gurwith; Jakub K Simon; Glenn Ishioka; Mitchell B Cohen; Beth D Kirkpatrick; Caroline E Lyon; Wilbur H Chen; Marcelo B Sztein; Myron M Levine; Jason B Harris
Journal:  Vaccine       Date:  2018-04-11       Impact factor: 3.641

2.  Enumeration of Gut-Homing β7-Positive, Pathogen-Specific Antibody-Secreting Cells in Whole Blood from Enterotoxigenic Escherichia coli- and Vibrio cholerae-Infected Patients, Determined Using an Enzyme-Linked Immunosorbent Spot Assay Technique.

Authors:  Taufiqur Rahman Bhuiyan; Mohammad Rubel Hoq; Naoshin Sharmin Nishat; Deena Al Mahbuba; Rasheduzzaman Rashu; Kamrul Islam; Lazina Hossain; Ayan Dey; Jason B Harris; Edward T Ryan; Stephen B Calderwood; Ann-Mari Svennerholm; Firdausi Qadri
Journal:  Clin Vaccine Immunol       Date:  2015-10-28

3.  Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera.

Authors:  Taher Uddin; Amena Aktar; Peng Xu; Russell A Johnson; M Arifur Rahman; Daniel T Leung; Sadia Afrin; Aklima Akter; Mohammad Murshid Alam; Atiqur Rahman; Fahima Chowdhury; Ashraful I Khan; Taufiqur Rahman Bhuiyan; Meagan K Bufano; Rasheduzzaman Rashu; Yanan Yu; Ying Wu-Freeman; Jason B Harris; Regina C LaRocque; Richelle C Charles; Pavol Kováč; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri
Journal:  Am J Trop Med Hyg       Date:  2014-03-31       Impact factor: 2.345

4.  Lipopolysaccharide- and cholera toxin-specific subclass distribution of B-cell responses in cholera.

Authors:  F Qadri; F Ahmed; M M Karim; C Wenneras; Y A Begum; M Abdus Salam; M J Albert; J R McGhee
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

5.  Validation of a volunteer model of cholera with frozen bacteria as the challenge.

Authors:  D A Sack; C O Tacket; M B Cohen; R B Sack; G A Losonsky; J Shimko; J P Nataro; R Edelman; M M Levine; R A Giannella; G Schiff; D Lang
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

6.  The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.

Authors:  Luis García; Manuel Díaz Jidy; Hilda García; Boris L Rodríguez; Roberto Fernández; Gemma Año; Bárbara Cedré; Tania Valmaseda; Edith Suzarte; Margarita Ramírez; Yadira Pino; Javier Campos; Jorge Menéndez; Rodrigo Valera; Daniel González; Irma González; Oliver Pérez; Teresita Serrano; Miriam Lastre; Fernando Miralles; Judith Del Campo; Jorge Luis Maestre; José Luis Pérez; Arturo Talavera; Antonio Pérez; Karen Marrero; Talena Ledón; Rafael Fando
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

7.  Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.

Authors:  Russell A Johnson; Taher Uddin; Amena Aktar; M Mohasin; Mohammad Murshid Alam; Fahima Chowdhury; Jason B Harris; Regina C LaRocque; Meagan Kelly Bufano; Yanan Yu; Ying Wu-Freeman; Daniel T Leung; David Sarracino; Bryan Krastins; Richelle C Charles; Peng Xu; Pavol Kovác; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

Review 8.  Immunology of gut mucosal vaccines.

Authors:  Marcela F Pasetti; Jakub K Simon; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

9.  Genomic correlates of variability in immune response to an oral cholera vaccine.

Authors:  Partha P Majumder; Neeta Sarkar-Roy; Herman Staats; T Ramamurthy; Sujit Maiti; Goutam Chowdhury; Carol C Whisnant; K Narayanasamy; Diane K Wagener
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

10.  Complexity of rice-water stool from patients with Vibrio cholerae plays a role in the transmission of infectious diarrhea.

Authors:  Eric J Nelson; Ashrafuzzaman Chowdhury; Jason B Harris; Yasmin A Begum; Fahima Chowdhury; Ashraful I Khan; Regina C Larocque; Anne L Bishop; Edward T Ryan; Andrew Camilli; Firdausi Qadri; Stephen B Calderwood
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.